BALAXI PHARMACEUTICALS financials

·UnclassifiedChart ›
Latest results Q1 FY27 · Apr–Jun 2026
Revenue
₹80.7cr+14.1% on Q1 FY26
Net profit
₹1.3cr+347.6% on Q1 FY26
EBITDA margin
5.8%−0.1 pts on Q1 FY26
EPS
₹0.24+380.0% on Q1 FY26

Quarterly results

Every quarter ›
₹ croreQ1 FY27Q1 FY26Change
Revenue80.770.7+14.1%
EBITDA4.74.1+12.4%
EBITDA margin5.8%5.9%−0.1 pts
Profit before tax2.10.9+131.3%
Net profit1.30.3+347.6%
EPS₹0.24₹0.05+380.0%

Over time

Q1 FY27 · Apr–Jun 2026latest
Revenue₹80.7 crNet profit₹1.3 crNet margin1.6%

Amounts on the left scale in ₹ crore; per cent on the right, dashed. L = lakh crore, K = thousand crore. Touch the chart to read any period.

Key numbersby financial year

₹ crore except per share
Tap a line for its trendCurrentlast 12MFY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023FY22 and earlierAlpha Plus
109————
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
14.614.639.462.328.2
55.855.851.617.711.6
150————
280270293241336
—−7.7%+21.2%−28.3%—
9.08.537.246.756.5
3.2%3.2%12.7%19.4%16.8%
6.56.435.344.654.8
2.41.425.1−2.446.0
0.9%0.5%8.6%−1.0%13.7%
₹0.44₹0.26₹4.54−₹0.43₹8.33
—−94.3%+1,150.3%−105.2%—
—−4.5−35.04.96.1
—−14.9−1.4−0.7−10.8
−19.4−19.4−36.44.2−4.7
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

BALAXI₹19.71

BALAXI PHARMACEUTICALS LIMITED

· Unclassified
₹ CrorePeersPARSTEELCITYLATTEYSCROWNHECPROJECTHINDCONAIROLAMGROBTEAMcap ₹109 Cr
HighlightsEnterprise ValueMultiplesPer ShareAnnuals · FY-end closes
In ₹ Crore except Per Share
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Current/LTM
TTM · last close
Market Capitalization————108.8
- Cash, Equiv & ST Investments28.262.339.414.614.6
+ Total Debt11.617.751.655.855.8
Enterprise Value————150.0
Revenue336.4241.3292.6270.2280.1
Growth %, YoY—-28.3+21.2-7.7—
EBITDA56.546.737.28.59.0
Margin %16.8119.3712.723.163.23
EBIT54.844.635.36.46.5
Net Income46.0-2.425.11.42.4
Margin %13.66-0.998.570.520.87
EPS, Adj (current shares)8.33-0.434.540.260.44
Growth %, YoY—-105.2+1,150.3-94.3—
Cash from Operations6.14.9-35.0-4.5—
Capital Expenditures-10.8-0.7-1.4-14.9—
Free Cash Flow-4.74.2-36.4-19.4-19.4
Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.

BALAXI PHARMACEUTICALS financials and key ratios

Prices at the 29 October 2026 close · figures from the company's filings with NSE

BALAXI PHARMACEUTICALS (NSE: BALAXI) had a market capitalisation of ₹106 crore at the 29 October 2026 close (₹19.15 a share), a PE ratio of 43.6 on the last four quarters' profit and a price-to-book ratio of 0.42. In FY26 its consolidated net profit was ₹1.4 crore on revenue of ₹270 crore; in Q1 FY27 (April–June 2026) it was ₹1.3 crore, up 347.6% year on year. Its debt-to-equity ratio was 0.22 on 31 March 2026. Promoters held 65.99% of the shares on 30 September 2026.

Share price used
₹19.15 · 29 October 2026 close
Latest balance sheet
31 March 2026
Shareholding pattern
30 September 2026

BALAXI PHARMACEUTICALS at a glance · consolidated

Market cap
₹106 Crat ₹19.15 · 29 Oct close
PE ratio (last 4 quarters)
43.674.6 on FY26 profit
Price to book (PB)
0.42book value ₹45.12 a share
ROE (FY26)
0.6%−11.0 pts vs FY25ROCE 2.4%
Debt to equity
0.22net debt ₹41.2 Cr
Promoter holding
65.99%unchanged vs 30 Jun 202630 September 2026
Net worth
₹249 Cr+7.5% vs 31 Mar 202531 March 2026
Free cash flow (FY26)
−₹19.4 Cr
EPS (FY26)
₹0.26

Questions

What is the BALAXI PHARMACEUTICALS PE ratio today?

BALAXI PHARMACEUTICALS's PE ratio is 43.6 at the 29 October 2026 close (₹19.15 a share): a market capitalisation of ₹106 crore divided by consolidated net profit of ₹2.4 crore over the last four quarters (Q2 FY26 to Q1 FY27). On FY26 net profit (₹1.4 crore) it is 74.6.

What is the BALAXI PHARMACEUTICALS PB ratio (price to book value)?

BALAXI PHARMACEUTICALS's price-to-book (PB) ratio is 0.42 at the 29 October 2026 close: a market capitalisation of ₹106 crore divided by shareholders' equity (book value) of ₹249 crore on 31 March 2026. That is a book value of ₹45.12 per share against a share price of ₹19.15.

What is the BALAXI PHARMACEUTICALS book value per share?

BALAXI PHARMACEUTICALS's book value per share was ₹45.12 on 31 March 2026: shareholders' equity of ₹249 crore divided by the 5.52 crore shares in issue, up 7.5% from ₹41.98 a year earlier. The share price at the 29 October 2026 close was ₹19.15.

What is the BALAXI PHARMACEUTICALS market cap?

BALAXI PHARMACEUTICALS's market capitalisation was ₹106 crore at the 29 October 2026 close: 5.52 crore shares at ₹19.15 each.

Is BALAXI PHARMACEUTICALS debt free?

No. BALAXI PHARMACEUTICALS had borrowings of ₹55.8 crore on 31 March 2026 (consolidated balance sheet), a debt-to-equity ratio of 0.22. Its cash and current investments were ₹14.6 crore, so its net debt was ₹41.2 crore.

What is the BALAXI PHARMACEUTICALS EPS?

BALAXI PHARMACEUTICALS's basic earnings per share (EPS) were ₹0.26 in FY26, against ₹4.54 in FY25. Over the last four quarters (Q2 FY26 to Q1 FY27) they add up to ₹0.45.

What is the BALAXI PHARMACEUTICALS debt to equity ratio?

BALAXI PHARMACEUTICALS's debt-to-equity ratio was 0.22 on 31 March 2026: borrowings of ₹55.8 crore against total equity of ₹249 crore. A year earlier, on 31 March 2025, it was 0.22.

What is the BALAXI PHARMACEUTICALS net worth?

BALAXI PHARMACEUTICALS's net worth — shareholders' equity in its consolidated balance sheet — was ₹249 crore on 31 March 2026, up 7.5% from ₹232 crore a year earlier. Its market value is a different figure: a market capitalisation of ₹106 crore at the 29 October 2026 close.

What is the BALAXI PHARMACEUTICALS promoter holding?

Promoters held 65.99% of BALAXI PHARMACEUTICALS on 30 September 2026, unchanged from both the previous quarter and a year earlier, according to the shareholding pattern filed with NSE.

What is the BALAXI PHARMACEUTICALS ROE and ROCE?

In FY26, BALAXI PHARMACEUTICALS's return on equity (ROE) was 0.6% and its return on capital employed (ROCE) was 2.4%. ROE is net profit divided by average shareholders' equity (the start and end of the year); ROCE is operating profit (EBIT) divided by average capital employed (total assets less current liabilities). In FY25, ROE was 11.6% and ROCE 15.4%.

What is the BALAXI PHARMACEUTICALS shareholding pattern?

On 30 September 2026, BALAXI PHARMACEUTICALS's shares were held by promoters 65.99%, foreign portfolio investors (FII/FPI) 0.00%, domestic institutions (DII) 2.56% and retail and other non-institutional investors 31.45%. Over the year, FII holding was down 3.50 percentage points from 3.50% and DII holding was up 2.54 percentage points from 0.02%.

How does the BALAXI PHARMACEUTICALS PE ratio compare with its peers?

At the 29 October 2026 closing prices, on FY26 net profit, BALAXI PHARMACEUTICALS's PE ratio is 74.6, the highest of the four: Par Drugs And Chemicals 10.8, Steel City Securities 8.1 and Latteys Industries 29.5, a peer average of 16.1. Each is the company's market capitalisation at that price divided by its FY26 net profit.

What is the BALAXI PHARMACEUTICALS free cash flow?

In FY26, BALAXI PHARMACEUTICALS generated ₹4.5 crore of cash from operations and spent ₹14.9 crore on capital expenditure (property, plant, equipment and intangibles), leaving free cash flow of −₹19.4 crore. In FY25 it was −₹36.4 crore.

What are the BALAXI PHARMACEUTICALS latest quarterly results?

BALAXI PHARMACEUTICALS's latest results are for Q1 FY27 (April–June 2026), filed on 5 August 2026: consolidated net profit ₹1.3 crore, up 347.6% from ₹29 lakh in Q1 FY26; revenue from operations ₹80.7 crore, up 14.1% year on year.

What is the BALAXI PHARMACEUTICALS revenue and profit in FY26?

In FY26 (April 2025–March 2026), BALAXI PHARMACEUTICALS's consolidated net profit was ₹1.4 crore, down 94.3% from ₹25.1 crore in FY25, on revenue from operations of ₹270 crore (down 7.7%). Over three years, from FY23, net profit was down 96.9%.

When are the BALAXI PHARMACEUTICALS next results?

BALAXI PHARMACEUTICALS will announce its Q2 FY27 results (July–September 2026) on Thursday, 12 November 2026, the date of the board meeting it has notified to the exchanges.

How does BALAXI PHARMACEUTICALS compare with its peers?

On FY26 consolidated figures, against Par Drugs And Chemicals, Steel City Securities and Latteys Industries: BALAXI PHARMACEUTICALS's operating margin of 2.4% is the lowest of the four (Par Drugs And Chemicals 13.0%, Steel City Securities 25.4%, Latteys Industries 5.2%; peer average 14.5%); its return on equity of 0.6% is the lowest of the four (Par Drugs And Chemicals 12.4%, Steel City Securities 10.8%, Latteys Industries 16.1%; peer average 13.1%).

BALAXI PHARMACEUTICALS vs Par Drugs And Chemicals: how do they compare?

In FY26, BALAXI PHARMACEUTICALS earned net profit of ₹1.4 crore on revenue of ₹270 crore, against ₹13.1 crore on ₹104 crore for Par Drugs And Chemicals. BALAXI PHARMACEUTICALS's operating margin was 2.4% (Par Drugs And Chemicals 13.0%) and its return on equity 0.6% (Par Drugs And Chemicals 12.4%). At the 29 October 2026 close, BALAXI PHARMACEUTICALS's market capitalisation was ₹106 crore against ₹141 crore for Par Drugs And Chemicals, and its PE ratio on FY26 profit 74.6 against 10.8.

Where do these BALAXI PHARMACEUTICALS figures come from?

From BALAXI PHARMACEUTICALS's own consolidated results, balance sheets and shareholding patterns filed with NSE, and NSE prices (the latest used here: the 29 October 2026 close). Ratios are calculated by Alphave from those filings as each answer describes.

Consolidated figures from the company's filings with NSE; prices are NSE closing prices.